Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
PPAR Res. 2008;2008:932632. doi: 10.1155/2008/932632. Epub 2008 Dec 14.
Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-activated transcription factor, which belongs to the family of nuclear hormone receptors. Recent in vitro studies have shown that PPARgamma can regulate the transcription of phosphatase and tensin homolog on chromosometen (PTEN), a known tumor suppressor. PTEN is a susceptibility gene for a number of disorders, including breast and thyroid cancer. Activation of PPARgamma through agonists increases functional PTEN protein levels that subsequently induces apoptosis and inhibits cellular growth, which suggests that PPARgamma may be a tumor suppressor. Indeed, several in vivo studies have demonstrated that genetic alterations of PPARgamma can promote tumor progression. These results are supported by observations of the beneficial effects of PPARgamma agonists in the in vivo cancer setting. These studies signify the importance of PPARgamma and PTEN's interaction in cancer prevention.
过氧化物酶体增殖物激活受体 γ（PPARγ）是一种配体激活的转录因子，属于核激素受体家族。最近的体外研究表明，PPARγ 可以调节染色体上磷酸酶和张力蛋白同源物（PTEN）的转录，PTEN 是许多疾病的易感基因，包括乳腺癌和甲状腺癌。通过激动剂激活 PPARγ 会增加功能性 PTEN 蛋白水平，随后诱导细胞凋亡并抑制细胞生长，这表明 PPARγ 可能是一种肿瘤抑制因子。事实上，几项体内研究表明，PPARγ 的遗传改变可促进肿瘤进展。这些结果得到了体内癌症环境中 PPARγ 激动剂有益作用的观察结果的支持。这些研究表明了 PPARγ 和 PTEN 相互作用在癌症预防中的重要性。
